Long-Term Renal Safety of 177Lu-Dotatate in Patients with CKD: A Five-Year Follow-Up Study (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO1165; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "These findings challenge the current paradigm of CKD focused renal surveillance and call for prospective studies incorporating extended follow up and more sensitive renal biomarkers to fully characterize the nephrotoxic potential of this therapy across the spectrum of kidney function. Acknowledging these limitations and the need for further study, 177Lu Dotatate remains a viable treatment option for patients with NETs and pre-existing CKD."
Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Renal Disease
|
|
Krupa Hareshkumar Savani; Zhihui Fang; Timothy Hobday; Thor R. Halfdanarson; Ayse Tuba Kendi; Geoffrey B. Johnson; Nelson Leung; Sandhya Manohar
|